Latest Licensing News

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.

PlaySide Studios reported a sharp 28% revenue decline for H1 FY26 but posted a remarkable 249% jump in profit, buoyed by cost cuts and a $7.8 million tax rebate. The company also secured a $6 million loan and inked a new global publishing deal.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

Paladin Energy has achieved a significant regulatory milestone with formal environmental approval for its Patterson Lake South uranium project in Saskatchewan, Canada, paving the way for construction licensing.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

LaserBond Ltd has reported a robust first half of FY26, with revenue up 13.4% and net profit after tax more than doubling, underpinned by a significant licensing agreement with Komatsu and ongoing R&D investments.

Arovella Therapeutics reported a 22% increase in half-year losses to $1.88 million while securing FDA acceptance of its IND application for lead asset ALA-101, paving the way for first-in-human trials.

McLaren Minerals has kicked off a major drilling campaign at its McLaren Titanium Project aiming to upgrade resource classifications and expand its substantial 529 million tonne resource base. The program is a critical step toward advancing the project’s development and future feasibility studies.